(2015) 112:E5664
As a consequence, levels of adherence are lower than for people with diabetes, as demonstrated by another study that applied the same metric of adherence to people using GLP-1s to treat obesity: 40.1% for Ozempic (semaglutide, Novo Nordisk), 31.5% for weekly injectable Wegovy and just 15% for daily injectable Saxenda (liraglutide, Novo Nordisk).10 This suggests that greater expectation management is required to maintain users faith in the value and purpose of what they are doing
Its a maths-only helper for research notes, not dosing advice
Common Side Effects to Watch While Using Wegovy Beyond hair loss, patients should monitor for these common side effects: Gastrointestinal Effects (Most Common) Nausea (44% of patients) Diarrhea (30% of patients) Vomiting (24% of patients) Constipation (24% of patients) Abdominal pain (20% of patients) Other Notable Side Effects Fatigue and weakness Headaches Dizziness Injection site reactions Decreased appetite (intended effect) When to Contact Your Intermediary Organization Severe or persistent nausea/vomiting Signs of pancreatitis (severe abdominal pain) Kidney problems (changes in urination) Allergic reactions (rash, swelling, difficulty breathing) Significant mood changes or depression Managing Hair Loss During Treatment Proactive management of hair health while using Wegovy can significantly reduce the severity and duration of hair loss

The actual pattern shows rapid early loss, peak velocity between weeks 12 and 24, gradual deceleration from weeks 24 through 40, and plateau from weeks 40 to 48